Deep Track Capital LP Acquires 800,216 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Deep Track Capital LP boosted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 116.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,490,000 shares of the company's stock after purchasing an additional 800,216 shares during the quarter. Akero Therapeutics comprises 1.5% of Deep Track Capital LP's portfolio, making the stock its 21st largest position. Deep Track Capital LP owned about 2.13% of Akero Therapeutics worth $41,452,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Akero Therapeutics by 13.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,321,972 shares of the company's stock valued at $120,238,000 after purchasing an additional 513,613 shares during the period. Vanguard Group Inc. grew its position in Akero Therapeutics by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 3,704,411 shares of the company's stock valued at $103,057,000 after buying an additional 27,830 shares in the last quarter. Rock Springs Capital Management LP lifted its stake in Akero Therapeutics by 1.4% during the fourth quarter. Rock Springs Capital Management LP now owns 946,499 shares of the company's stock valued at $26,332,000 after purchasing an additional 13,100 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Akero Therapeutics during the fourth quarter valued at approximately $18,059,000. Finally, Northern Trust Corp lifted its stake in Akero Therapeutics by 6.1% in the 4th quarter. Northern Trust Corp now owns 620,321 shares of the company's stock worth $17,257,000 after acquiring an additional 35,737 shares in the last quarter.

Akero Therapeutics Trading Up 4.5%

NASDAQ AKRO traded up $1.78 during mid-day trading on Monday, reaching $41.63. 823,512 shares of the stock were exchanged, compared to its average volume of 891,283. The stock has a market cap of $3.32 billion, a P/E ratio of -11.10 and a beta of -0.12. The stock has a 50 day simple moving average of $41.21 and a 200-day simple moving average of $37.56. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a one year low of $17.86 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Insider Activity

In other Akero Therapeutics news, insider Catriona Yale sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $49.87, for a total value of $498,700.00. Following the sale, the insider now directly owns 95,648 shares in the company, valued at $4,769,965.76. This represents a 9.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Patrick Lamy sold 8,000 shares of the company's stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $42.49, for a total value of $339,920.00. Following the completion of the transaction, the vice president now owns 33,492 shares in the company, valued at $1,423,075.08. This represents a 19.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 189,208 shares of company stock valued at $7,974,594 in the last 90 days. Insiders own 7.94% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AKRO. Citigroup raised their price target on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Canaccord Genuity Group boosted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. HC Wainwright raised their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Finally, Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.